Á¦2Çü ´ç´¢º´ ȯÀÚ¿¡¼ ½ÃŸ±Û¸³Æ¾°ú ¸ÞÆ®Æ÷¹Î °íÁ¤ º¹ÇÕÁ¦ Åõ¿©¿Í ´ÜÀÏÁ¦ º´¿ë°£ÀÇ º¹¾à ¼øÀÀµµ, È¿°ú ¹× ¾à°¡¿¡ ´ëÇÑ ºñ±³ ¿¬±¸
Comparisons of Adherence, Efficacy and Price between Sitagliptin/Metformin Fixed-dose Combination Tablets and Concomitant Administration of Sitagliptin and Metformin in Type 2 Diabetes Mellitus Patients
Çѱ¹ÀÓ»ó¾àÇÐȸÁö 2014³â 24±Ç 3È£ p.193 ~ p.198
¹ÚÁöÇý(Park Ji-Hye) - ¼¿ï¾Æ»êº´¿ø ¾àÁ¦ÆÀ
À̺´±¸(Lee Byung-Koo) - ÀÌÈ¿©ÀÚ´ëÇб³ ¾àÇдëÇÐ
±èÀ翬(Kim Jae-Yeun) - ¼¿ï¾Æ»êº´¿ø ¾àÁ¦ÆÀ
°ûÇý¼±(Kwak Hye-Seon) - ÀÌÈ¿©ÀÚ´ëÇб³ ¾àÇдëÇÐ
Abstract
Objective: This study was conducted to compare the adherence, clinical and economical utility of fixed-dose combination tablets of sitagliptin/metformin with concomitant administration of sitagliptin and metformin in patients with type 2 diabetes mellitus.
Methods: Adherence was measured as the medication possession ratio (MPR) of ¡Ã80%, and MPR was calculated as the number of total prescription days divided by the total treatment period. Hemoglobin A1C (HbA1c) differences between baseline and predetermined periods were analyzed. Proportions of patients who achieved HbA1c less than 6.5% for three or more consecutive times were compared. To evaluate cost-effectiveness, prices of sitagliptin, metformin and sitagliptin/metformin tablets were investigated.
Results: More than 90% of patients showed adherence in both groups (92.0% in fixed-dose combination group vs 95.9% in concomitant administration group), and there was no statistically significant difference (P = 0.113). Proportion of patients with HbA1c less than 6.5% for three or more consecutive times tended to be somewhat higher in fixed dose combination group than in concomitant administration group without a statistically significant difference (32.6% vs. 28.0%, P = 0.344). Total price of metformin and sitagliptin was cheaper up to 222 KRW in the case of fixed-dose combination tablets compared to the case of concomitant administration.
Conclusion: The sitagliptin/metformin fixed-dose combination tablet had a similar patient adherence and was not
significantly different in efficacy to the concomitant administration of each component. In terms of drug prices, fixeddose
combination tablets were cheaper than concomitant administration of each tablet.
Å°¿öµå
sitagliptin, metformin, fixed-dose combination, concomitant administration, adherence, efficacy, price
KMID :
0941820140240030193
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)